A Phase 1 interventional study of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells in Skin Ulcer, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Not yet recruiting at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by The Foundation for Orthopaedics and Regenerative Medicine · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Skin Ulcer with a site in United States — 8 open to participants now, 10 under way, 1 of them phase 3. Skin Ulcer · United States.
Among the 21 studies in Skin Ulcer with a site in United States, this one is the 15th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 1, and was the 11th registered.
61 studies on the registry are indexed under Skin Ulcer; 14 are open to participants now.
Browse Skin Ulcer studies →8 of the 21 studies in Skin Ulcer with a site in United States are open now. Recruiting first, the newest first:
Sequence LifeScience, Inc. · Sites in United States
Ages 18+
Samaritan Biologics · Sites in United States
Ages 18+
C5 Biomedical · Sites in United States
Ages 18+
Tides Medical · Sites in United States
Ages 18+
Axolotl Biologix · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Skin Ulcer studies recruiting now, 9 (90%) set no upper age limit and 1 (10%) stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 62 across 51 interventional studies indexed under Skin Ulcer.
Median enrollment 88 across the 18 interventional studies, 150,500 across the 2 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
The Foundation for Orthopaedics and Regenerative Medicine is the lead sponsor of 33 studies on the registry; 19 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
The Foundation for Orthopaedics and Regenerative Medicine has 1 study filed under Skin Ulcer — fewer than ten, so there is no comparison to draw.
5 of the studies in Skin Ulcer with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06489028Phase 3RHEACELL GmbH & Co. KGAllogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III) | 2027-04 |
| NCT06674980C5 BiomedicalClinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs | 2026-11-22 |
| NCT06437028Samaritan BiologicsEvaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers. | 2027-03 |
| NCT06563323Oregon Health and Science UniversityGuselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) | 2027-08-13 |
| NCT07290673Samaritan BiologicsEvaluating the Efficacy of FoundationDRS Solo in Addition to Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 21 studies in Skin Ulcer with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial will study the safety and efficacy of intravenous infusion and intralesional injection of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Skin Ulcer
This patient funded trial aims to study the safety and efficacy of intravenous infusion and intralesional injection of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells (MSCs) for the treatment of Skin Ulcer. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intravenous infusion and intralesional injection of 100 million cells
Biological: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
Safety (adverse events)
Clinical monitoring of possible adverse events or complications
Time frame: Four year follow-up
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Dec 2026, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Foundation for Orthopaedics and Regenerative Medicine